Filter posts

Biopharma Steps Up as Diabetes Epidemic Goes Global

This May, the World Health Organization (WHO) named its new Director-General Dr. Tedros Adhanom Chebreyesus, …

What's Driving Health Care Spending? Hint: Not Drug Costs.

With health care costs an important concern for many Americans, a common misperception is the …

ICYMI: Jim Greenwood Weighs In on the Future of Drug Pricing

Rewarding for quality – not quantity – is becoming more and more common in health …

#BIO2017 Fireside Chat: Unlocking the Power of the Genome

To Francis deSouza, genomics is a transformational force. deSouza, President and CEO of Illumina, joined …

8 Reasons New Medicines are Needed for Alzheimer’s

Last week, the Alzheimer’s Association released an infographic with eight mythbusting facts to help dispel …

Biotech Solutions for Zika

The Zika virus epidemic continues to rage on. Just today, the WHO advised people in Zika affected …

Strategic Venture Investing by Large Pharma: Is “Smart Money” Right for Your Company

The strategic venture arms of major biopharma companies like AbbVie, Amgen, Johnson & Johnson and …

Yoshinori Ohsumi, Ph.D., Receives 2016 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson presented cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology, …

Nailed It! Rock Star Panel

Today’s “Nailed It! Rock Star Panel,” sponsored by Johnson & Johnson Innovation/JLABS, featured three company …

Curative Therapies: Aligning Policy with Science to Ensure Patient Access

New hepatitis C medications with exceptionally high cure rates have significantly improved treatment, while also …